Kos Therapeutics, Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
Mar 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 16, 2026The maintenance fee for Amino acid derivatives containing a disulfanyl group in the form of an NEP and APN inhibitor for the prevention and treatment of trigeminal nerve pain (US 11,648,231) comes due Nov 16, 2026. Unpaid by May 17, 2027, it lapses early.
- 1 fee due Mar 3, 2027The maintenance fee for Industrial process for the preparation of (5S, 10S)-10-benzyl-16-methyl-11, 14, 18-trioxo-15, 17, 19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium(E)-3-carboxyacrylate salt (US 10,399,936) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,247,609 | Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase N inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 8,466,309 | Amino acid derivatives, method for preparing same, and therapeutic use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,247,608 | Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase N inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,131,681 | Aminophosphinic derivatives that can be used in the treatment of pain In force · From the USPTO record | In force | From the USPTO record | |
| US 8,703,747 | Aminophosphinic derivatives that can be used in the treatment of pain In force · From the USPTO record | In force | From the USPTO record | |
| US 9,388,129 | Mixed inhibitors of aminopeptidase N and neprilysin In force · From the USPTO record | In force | From the USPTO record | |
| US 10,399,936 | Industrial process for the preparation of (5S, 10S)-10-benzyl-16-methyl-11, 14, 18-trioxo-15, 17, 19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium(E)-3-carboxyacrylate salt In force · From the USPTO record | In force | From the USPTO record | |
| US 11,648,231 | Amino acid derivatives containing a disulfanyl group in the form of an NEP and APN inhibitor for the prevention and treatment of trigeminal nerve pain In force · From the USPTO record | In force | From the USPTO record | |
| US 12,391,710 | Method for the Industrial Preparation of the Disodium Salt of ((2S)-3-([1,1'-Biphenyl]-4-YL)-2-((HYDROXY((1R)-1-(((1-(ISOBUTYRYLOXY)ETHOXY)CARBONYL)AMINO)ETHYL)PHOSPHORYL) Methyl)propanoyl)-L-Alanine In force · High confidence | In force | High confidence | |
| US 12,753,149 | N-Formylhydroxylamines as Neprilysin (NEP) Inhibitors, in Particular as Mixed Aminopeptidase N (APN) and Neprilysin (NEP) Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 10: 1 patent in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.